{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:31:18Z","timestamp":1792985478991,"version":"4.5.0"},"reference-count":82,"publisher":"European Respiratory Society (ERS)","issue":"151","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2019,1,7]]},"published-print":{"date-parts":[[2019,3,31]]},"abstract":"<jats:p>Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function, worsening quality of life, and early mortality. It has been proposed that such progressive fibrosing ILDs, which show commonalities in clinical behaviour and in the pathogenetic mechanisms that drive progressive fibrosis, may be \u201clumped\u201d together for the purposes of clinical research and, potentially, for treatment. At present, no drugs are approved for the treatment of ILDs other than nintedanib and pirfenidone for the treatment of idiopathic pulmonary fibrosis. For other progressive fibrosing ILDs, the mainstay of drug therapy is immunosuppression. However, it is postulated that, once the response to lung injury in fibrosing ILDs has reached the stage at which fibrosis has become progressive and self-sustaining, targeted antifibrotic therapy would be required to slow disease progression. Nintedanib, an intracellular inhibitor of tyrosine kinases, has shown antifibrotic, anti-inflammatory and vascular remodelling effects in several non-clinical models of fibrosis, irrespective of the trigger for the injury. Ongoing clinical trials will provide insight into the role of antifibrotic treatment with nintedanib or pirfenidone in the management of fibrosing ILDs with a progressive phenotype.<\/jats:p>","DOI":"10.1183\/16000617.0100-2018","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T03:34:11Z","timestamp":1551324851000},"page":"180100","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":318,"title":["Fibrosing interstitial lung diseases: knowns and unknowns"],"prefix":"10.1183","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Wollin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryeh","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Quaresma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Stowasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8629-7391","authenticated-orcid":false,"given":"Sergio","family":"Harari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"key":"2024102403381417000_28.151.180100.1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2024102403381417000_28.151.180100.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2024102403381417000_28.151.180100.3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/resp.12674","article-title":"Idiopathic non-specific interstitial pneumonia","volume":"21","author":"Belloli","year":"2016","journal-title":"Respirology"},{"key":"2024102403381417000_28.151.180100.4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/resp.12931","article-title":"Unclassifiable interstitial lung diseases: clinical characteristics and survival","volume":"22","author":"Hyldgaard","year":"2017","journal-title":"Respirology"},{"key":"2024102403381417000_28.151.180100.5","first-page":"2","article-title":"Assessment and management of connective tissue disease-associated interstitial lung disease","volume":"32","author":"Fischer","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2024102403381417000_28.151.180100.6","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201303-069FR"},{"key":"2024102403381417000_28.151.180100.7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2685"},{"key":"2024102403381417000_28.151.180100.8","doi-asserted-by":"publisher","DOI":"10.1080\/01926230601064787"},{"key":"2024102403381417000_28.151.180100.9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000212"},{"key":"2024102403381417000_28.151.180100.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00692-2018"},{"key":"2024102403381417000_28.151.180100.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0840OC"},{"key":"2024102403381417000_28.151.180100.12","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1513\/AnnalsATS.201606-458OC","article-title":"Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis","volume":"14","author":"Paterniti","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2024102403381417000_28.151.180100.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"2024102403381417000_28.151.180100.14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201403-0566OC"},{"key":"2024102403381417000_28.151.180100.15","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00108111"},{"key":"2024102403381417000_28.151.180100.16","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00096-2016"},{"key":"2024102403381417000_28.151.180100.17","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-0844"},{"key":"2024102403381417000_28.151.180100.18","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2015-207011"},{"key":"2024102403381417000_28.151.180100.19","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/rccm.201511-2152OC","article-title":"Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis","volume":"194","author":"Russell","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403381417000_28.151.180100.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02406-2016"},{"key":"2024102403381417000_28.151.180100.21","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e328363f4b7"},{"key":"2024102403381417000_28.151.180100.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201601-0169CI"},{"key":"2024102403381417000_28.151.180100.23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000475780","article-title":"Idiopathic pulmonary fibrosis: molecular endotypes of fibrosis stratifying existing and emerging therapies","volume":"93","author":"Magnini","year":"2017","journal-title":"Respiration"},{"key":"2024102403381417000_28.151.180100.24","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00005512"},{"key":"2024102403381417000_28.151.180100.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.8.722"},{"key":"2024102403381417000_28.151.180100.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.10794"},{"key":"2024102403381417000_28.151.180100.27","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.00002015"},{"key":"2024102403381417000_28.151.180100.28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003569"},{"key":"2024102403381417000_28.151.180100.29","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00150-2015"},{"key":"2024102403381417000_28.151.180100.30","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0139-2017"},{"key":"2024102403381417000_28.151.180100.31","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0047-2018"},{"key":"2024102403381417000_28.151.180100.32","doi-asserted-by":"crossref","first-page":"e0163894","DOI":"10.1371\/journal.pone.0163894","article-title":"Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study","volume":"11","author":"Jaeger","year":"2016","journal-title":"PLoS One"},{"key":"2024102403381417000_28.151.180100.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.114264"},{"key":"2024102403381417000_28.151.180100.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211448"},{"key":"2024102403381417000_28.151.180100.35","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200706-877OC"},{"key":"2024102403381417000_28.151.180100.36","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201004-0622OC"},{"key":"2024102403381417000_28.151.180100.37","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","article-title":"MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease","volume":"379","author":"Juge","year":"2018","journal-title":"N Engl J Med"},{"key":"2024102403381417000_28.151.180100.38","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/art.40574","article-title":"The lung in rheumatoid arthritis: focus on interstitial lung disease","volume":"70","author":"Spagnolo","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2024102403381417000_28.151.180100.39","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.39971","article-title":"Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease","volume":"69","author":"Zamora-Legoff","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024102403381417000_28.151.180100.40","first-page":"103","article-title":"Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia","volume":"30","author":"Song","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2024102403381417000_28.151.180100.41","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01565-2015"},{"key":"2024102403381417000_28.151.180100.42","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00131912"},{"key":"2024102403381417000_28.151.180100.43","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12234"},{"key":"2024102403381417000_28.151.180100.44","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00357-2015"},{"key":"2024102403381417000_28.151.180100.45","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.096677"},{"key":"2024102403381417000_28.151.180100.46","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209909"},{"key":"2024102403381417000_28.151.180100.47","doi-asserted-by":"publisher","DOI":"10.1002\/art.22204"},{"key":"2024102403381417000_28.151.180100.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"2024102403381417000_28.151.180100.49","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102403381417000_28.151.180100.50","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology"},{"key":"2024102403381417000_28.151.180100.51","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170541"},{"key":"2024102403381417000_28.151.180100.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2024102403381417000_28.151.180100.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2024102403381417000_28.151.180100.54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000289"},{"key":"2024102403381417000_28.151.180100.55","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201203-0513CI"},{"key":"2024102403381417000_28.151.180100.56","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(16)30033-9","article-title":"Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study","volume":"4","author":"Walsh","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102403381417000_28.151.180100.57","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S2213-2600(13)70191-7","article-title":"Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study","volume":"1","author":"Morell","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2024102403381417000_28.151.180100.58","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201611-2201PP","article-title":"Hypersensitivity pneumonitis: perspectives in diagnosis and management","volume":"196","author":"Va\u0161\u00e1kov\u00e1","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403381417000_28.151.180100.59","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1164\/rccm.201608-1675PP","article-title":"Diagnosis and treatment of fibrotic hypersensitivity pneumonia. Where we stand and where we need to go","volume":"196","author":"Salisbury","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403381417000_28.151.180100.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.12.030"},{"key":"2024102403381417000_28.151.180100.61","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2442060640"},{"key":"2024102403381417000_28.151.180100.62","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.chest.2017.02.011","article-title":"Pathologic findings and prognosis in a large prospective cohort of chronic hypersensitivity pneumonitis","volume":"152","author":"Wang","year":"2017","journal-title":"Chest"},{"key":"2024102403381417000_28.151.180100.63","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S2213-2600(17)30216-3","article-title":"The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study","volume":"5","author":"Ley","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024102403381417000_28.151.180100.64","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.chest.2016.10.029","article-title":"Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis","volume":"151","author":"Morisset","year":"2017","journal-title":"Chest"},{"key":"2024102403381417000_28.151.180100.65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6307"},{"key":"2024102403381417000_28.151.180100.66","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.244129"},{"key":"2024102403381417000_28.151.180100.67","first-page":"PA903","article-title":"Nintedanib inhibits pro-fibrotic mediators from T cells with relevance to connective tissue disease-associated interstitial lung disease","volume":"50","author":"Wollin","year":"2017","journal-title":"Eur Respir J"},{"key":"2024102403381417000_28.151.180100.68","first-page":"A2397","article-title":"Nintedanib attenuates the polarization of profibrotic macrophages through the inhibition of tyrosine phosphorylation on CSF1 receptor","volume":"195","author":"Tandon","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403381417000_28.151.180100.69","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210823"},{"key":"2024102403381417000_28.151.180100.70","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12931-017-0654-2","article-title":"Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity","volume":"18","author":"Sato","year":"2017","journal-title":"Respir Res"},{"key":"2024102403381417000_28.151.180100.71","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12931-014-0157-3","article-title":"Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis","volume":"5","author":"Hostettler","year":"2014","journal-title":"Respir Res"},{"key":"2024102403381417000_28.151.180100.72","first-page":"A2008","article-title":"Nintedanib attenuates motility of lung fibroblasts from patients with idiopathic pulmonary fibrosis","volume":"189","author":"Wollin","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403381417000_28.151.180100.73","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00174914"},{"key":"2024102403381417000_28.151.180100.74","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207109"},{"key":"2024102403381417000_28.151.180100.75","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.208223"},{"key":"2024102403381417000_28.151.180100.76","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10456-017-9543-z","article-title":"Effects of nintedanib on the microvascular architecture in a lung fibrosis model","volume":"20","author":"Ackermann","year":"2017","journal-title":"Angiogenesis"},{"key":"2024102403381417000_28.151.180100.77","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/01902148.2017.1339141","article-title":"Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model","volume":"43","author":"Lee","year":"2017","journal-title":"Exp Lung Res"},{"key":"2024102403381417000_28.151.180100.78","doi-asserted-by":"crossref","first-page":"L998","DOI":"10.1152\/ajplung.00304.2017","article-title":"Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease","volume":"314","author":"Redente","year":"2018","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2024102403381417000_28.151.180100.79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103690"},{"key":"2024102403381417000_28.151.180100.80","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"},{"key":"2024102403381417000_28.151.180100.81","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1063ST"},{"key":"2024102403381417000_28.151.180100.82","first-page":"75","article-title":"Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS)","volume":"35","author":"Distler","year":"2017","journal-title":"Clin Exp Rheumatol"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0100-2018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:00:51Z","timestamp":1740373251000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0100-2018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":82,"journal-issue":{"issue":"151","published-online":{"date-parts":[[2019,2,27]]},"published-print":{"date-parts":[[2019,3,31]]}},"alternative-id":["10.1183\/16000617.0100-2018"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0100-2018","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,27]]}}}